hotspot -WSS

hotspot

author：Wikipedia 2025-09-27 10:03:10 - browse：76

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

WSS

WuXi Biologics execs register to lobby as Congress comes for the company

Fauci’s Covid grilling leads GOP to weigh foreign research rules

Lilly’s weekly insulin works as well as daily products, new studies show

The SUPPORT Act is critical to fighting the opioid crisis

Heart disease and mental health: A look at cardiac psychology

As JPM 2024 winds down, some health tech firms project optimism

hotspot

hotspot

explore

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Heart disease and mental health: A look at cardiac psychology

DIEP, the 'gold standard' of breast reconstruction, is under threat

Lilly’s weekly insulin works as well as daily products, new studies show

Walensky prepares to leave CDC — and Congress — behind

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Walensky prepares to leave CDC — and Congress — behind

Novo Nordisk testing Wegovy against alcohol

Medical leaders decry Supreme Court decision on affirmative action

STAT series 'Denied by AI' wins major journalism prizes

leisure time

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Free medical tuition alone isn't enough to close gaps in primary care

Doulas covered by Medicaid under New York's new plan

Fauci’s Covid grilling leads GOP to weigh foreign research rules

The nurse manager staffing crisis is hurting patients

Hottest summer in 2,000 years puts focus on extreme heat, health

entertainment

hotspot

Wikipedia

focus